Moteur de recherche d’entreprises européennes
UK funding (1 525 891 £) : Fabrication pharmaceutique secondaire avancée Ukri01/10/2009 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
Fabrication pharmaceutique secondaire avancée
| Abstract | In order to underpin the competitiveness of the UK pharmaceutical industry, a step change improvement in manufacturing efficiency is needed. This project aims to deliver this for production of the largest proportion of dosage forms (tablets). The efficiency gains are targeted at improved manufacturing precision, improved productivity and improved mass yield, and will be deliverable at approximately 70% of the capital cost of conventional technology. In developing this capability, significant technical knowledge to be delivered which will enhance the offering of the equipment manufacturers who are part of our consortium. The project will use advanced manufacturing equipment, process measurement, control and information management to deliver the claimed benefits. Previous work has been fragmented; this project will deliver an integrated advanced manufacturing / product release data acquisition platform. It is proposed to set up and use test facilities to prove the feasibility of the required manufacturing platform, enabling the optimal design of a commercial plant capable of making saleable product. The key deliverables are (i) an optimised integration strategy, (ii) performance benchmarks, (iii) a de-risked design for a full scale integrated facility, and (iv) data to demonstrate design effectiveness to key stakeholders including regulatory agencies. The process uses continuous twin screw granulation, fluid bed drying, inline blending and tablet compression, whilst PAT instruments along with standard process parameters such as temperature, pressure and work input are used to monitor the stability and control the process Product release is focused around real time continuous process monitoring and control. It is based on an understanding of the process acquired during the experimental trials following DfM/QbD principles. A concept factory of the future will be designed for the layout and operation of continuous OSD pharmaceutical manufacture. Peripheral work to the above this project will also is deliver a POC continuous tablet coater that coats at a rate to compliment the continuous trial equipment and a continuous powder blender. |
| Category | Collaborative R&D |
| Reference | 100736 |
| Status | Closed |
| Funded period start | 01/10/2009 |
| Funded period end | 31/03/2012 |
| Funded value | £1 525 891,00 |
| Source | https://gtr.ukri.org/projects?ref=100736 |
Participating Organisations
| Glaxosmithkline Plc | |
| University of Warwick |
£313 016,00 |
| Sagentia Limited |
£33 882,00 |
| Siemens Public Limited Company |
£128 240,00 |
| Newcastle University |
£220 753,00 |
| Gea Pharma Systems Limited |
£500 000,00 |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : GSK plc, Brentford, Royaume Uni.
Les visualisations de "Glaxosmithkline plc - UK funding (1 525 891 £) : Fabrication pharmaceutique secondaire avancée"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
